Novel opioid antagonists

Abstract

Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.

What is claimed: 
     
         1 . A compound of formula I: 
       
         
           
           
               
               
           
         
         wherein:
 R 1  is —C(═O)NH 2 ; 
 X is N—C(═O)-aryl; 
 or a pharmaceutically acceptable salt thereof. 
 
       
     
     
         2 . The compound of  claim 1 , wherein said aryl is substituted with halo. 
     
     
         3 . The compound of  claim 2 , wherein said aryl is substituted with fluoro. 
     
     
         4 . A method for treatinged Parkinson's disease comprising the step of administering a compound of the formula I 
       
         
           
           
               
               
           
         
         wherein:
 R 1  is —C(═O)NH 2 ; 
 X is N—C(═O)-aryl, said aryl substituted with fluoro; 
 or a pharmaceutically acceptable salt thereof. 
 
         or a pharmaceutically acceptable salt thereof to a patient receiving L-dopa. 
       
     
     
         5 . The method of  claim 4 , wherein the compound of formula I is administered as an adjunct to L-dopa for treatment of dyskinesia associated with the L-dopa treatment.